Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study of the Efficacy and Safety of Carbidopa-Levodopa Extended-Release Tablets in Patients With Parkinson's Disease
Sponsor: Shanghai WD Pharmaceutical Co., Ltd.
Summary
It is a phase II randomized, parallel, double-blind, placebo-controlled, multi-center clinical trial of the efficacy and safety of WD-1603 Carbidopa-Levodopa Extended-Release Tablets in patients with Parkinson's disease. The objective of the study is to access the safety and efficacy of WD-1603 carbidopa-levodopa extended-release tablets in patients with Parkinson's disease.
Official title: A Phase II Randomized, Parallel, Double-blind, Placebo-controlled, Multi-center Clinical Trial of the Efficacy and Safety of WD-1603 Carbidopa-Levodopa Extended-Release Tablets in Patients With Parkinson's Disease
Key Details
Gender
All
Age Range
30 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
40
Start Date
2021-11-25
Completion Date
2022-12-28
Last Updated
2026-10-07
Healthy Volunteers
No
Conditions
Interventions
WD-1603 Carbidopa-Levodopa Extended-Release Tablets
Taking WD-1603 tablets or placebo orally three times a day, in the morning before meals, and the second and third medications will be taken after meals, once every 5 hours (±30 minutes).
Placebo
placebo tablets-matching the active groups.
Locations (1)
Shanghai Huashan Hospital
Shanghai, Shanghai Municipality, China